LEADER 06060nam 2200673Ia 450 001 9910454831003321 005 20200520144314.0 010 $a1-280-04347-4 010 $a9786610043477 010 $a0-306-46885-9 024 7 $a10.1007/0-306-46885-9 035 $a(CKB)111056486604448 035 $a(EBL)3035433 035 $a(SSID)ssj0000212518 035 $a(PQKBManifestationID)11201677 035 $a(PQKBTitleCode)TC0000212518 035 $a(PQKBWorkID)10138496 035 $a(PQKB)10322648 035 $a(DE-He213)978-0-306-46885-8 035 $a(MiAaPQ)EBC3035433 035 $a(Au-PeEL)EBL3035433 035 $a(CaPaEBR)ebr10047429 035 $a(CaONFJC)MIL4347 035 $a(OCoLC)55663768 035 $a(EXLCZ)99111056486604448 100 $a20010308d2002 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aNovel frontiers in the production of compounds for biomedical use$b[electronic resource] /$fedited by Annie Van Broeckhoven, Fred Shapiro and Jozef Anne? 205 $a1st ed. 2002. 210 $aLondon ;$aDordrecht $cKluwer Academic$dc2002 215 $a1 online resource (460 p.) 225 1 $aFocus on biotechnology ;$vv. 1 300 $aCompilation of selected presentations given at the 9th European Congress on Biotechnology. 311 $a0-7923-6747-2 320 $aIncludes bibliographical references and index. 327 $aGenomics: the New Approach to the Discovery of New Compounds -- The Genomics Approach: Is it Really the Solution? -- The Contribution of Genomics to the Discovery of New Antibiotics -- Antibiotics -- The Antibiotic Gallidermin-Evolution of a Production Process -- Resistance to ?-Lactams, a Self-Regenerating Problem -- Resistance to aminoglycoside Antibiotics: Function meets structure -- The Genetics and Biochemistry of Resistance to Glycopeptide Antibiotics -- ?-Lactamases, an Old but Ever Renascent Problem -- Metabolic Flux Analysis in Streptomyces Coelicolor: Effect of nitrogen source -- Metabolic Engineering of the Lysine Pathway for ?-Lactam Overproduction in Penicillium Chrysogenum -- Glycosylation of Antibiotics and Other Agents from Actinomycetes -- Enzymatic Synthesis of Amoxicillin -- Production of Therapeutic Antibodies -- New Recombinant Bi- and Trispecific Antibody Derivatives -- Advantages of Single-Domain Antigen-Binding Fragments Derived from Functional Camel Heavy-Chain Antibodied -- Heterologous Protein Production: New Production Strategies -- Furin as a Tool for the Endoproteolytic Maturation of Susceptible Recombinant Biopharmaceuticals -- Development of Bioprocesses for the Generation of Anti-Inflammatory, Anti-Viral and Anti-Leukaemic Agents -- Apoptosis and Bioprocess Technology -- Gram-Positive Bacteria as Host Cells for Heterologous Production of Biopharmaceuticals -- Multiple Pathways of Exoprotein Secretion in Gram-Negative Bacteria -- Alteration of Metabolic Flux Distributions in Recombinant Escherichia Coli in Response to Heterologous Protein Production -- Dynamics of Proteolysis and its Influence on the Accumulation of Intracellular Recombinant Protein -- Artificial Organs and Xenografting -- The Impact of Transgenesis and Cloning on Cell and Organ Xenotransplantation to Humans -- Reinforced Bioartificial Skin in the Form of Collagen Sponge and Threads -- Antitumour Compounds -- Towards the Generation of Novel Antitumour Agents from Actinomycetes by Combinational Biosynthesis -- Cell Immobilisation of Taxus Media -- Pre and Probiotics -- The Role of Prebiotics in Human Gut Microbiology -- The Influence of Intestinal Microflora on Mucosal and Systemic Immune Responses. 330 $aThe present book entitled ?Novel Frontiers in the Production of Compounds for Biomedical Uses? can perhaps be placed in its best perspective by the Shakespearean character in The Tempest who exclaimed" What?s past is prologue?. Indeed, this compilation of some of the outstanding presentations in the field of biomedicine made at th the 9 European Congress on Biotechnology (Brussels, Belgium, July 11-15, 1999) not only reflects the achievements of the recent past, but provides a privileged glimpse of the biotechnology that is emerging in the first decade of the new Millennium. It is becoming increasingly apparent that biotechnology is offering biomedicine novel approaches and solutions to develop a sorely needed new generation of biopharmaceuticals. This is all the more necessary because in recent years, new diseases have emerged with extraordinary lethality in all corners of the globe, while age-related chronic illnesses have filled the gap wherever biomedicine has made successful inroads. The rise of antibiotic resistance also poses major threats to public health. Thus, as disease patterns evolve, the rational development of new drugs is becoming urgent, not only for the clinical outcome of patients, but also in optimising the allocation of scarce health care resources through the use of cost-effective productions methods. It is in response to all these challenges that biotechnology offers new strategies that go beyond the more traditional approaches. By the mid-1990?s, the number of recombinant products approved annually for therapeutic use reached double digits. With the advent of the genomics revolution. 410 0$aFocus on biotechnology ;$vv. 1. 606 $aPharmaceutical biotechnology 606 $aDrugs$xDesign 608 $aElectronic books. 615 0$aPharmaceutical biotechnology. 615 0$aDrugs$xDesign. 676 $a615.19 701 $aVan Broekhoven$b Annie$0854165 701 $aShapiro$b Fred$0854166 701 $aAnne?$b Jozef$0854167 712 12$aEuropean Congress on Biotechnology$d(9th :$f1999 :$eBrussels, Belgium) 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910454831003321 996 $aNovel frontiers in the production of compounds for biomedical use$91907323 997 $aUNINA